Social adjustment in generalised anxiety disorder: A long-term placebo-controlled study of venlafaxine extended release

European Psychiatry

Volumn 19, Issue 5, 2004, Pages 272-279

  Boyer, Patrice ^a   Mahé, Vincent ^b   Hackett, David ^c  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b HÔPITAL DU BOCAGE   (France)

^c Clinical Research and Development   (France)

Author keywords

Generalised anxiety disorder; Social impairment; Venlafaxine

Indexed keywords

PLACEBO; VENLAFAXINE;

ADULT; ARTICLE; BELGIUM; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DATA ANALYSIS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FAMILY; FEMALE; FINLAND; FRANCE; GENERALIZED ANXIETY DISORDER; HUMAN; LEISURE; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MARRIAGE; MULTICENTER STUDY; OUTPATIENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; REMISSION; SCORING SYSTEM; SELF REPORT; SHORT COURSE THERAPY; SOCIAL ADAPTATION; SOCIAL ASPECT; SOCIAL DISABILITY; SWEDEN; TREATMENT OUTCOME; UNITED KINGDOM; WORK;

ADJUSTMENT DISORDERS; ADOLESCENT; ADULT; AGED; ANXIETY DISORDERS; CYCLOHEXANOLS; DELAYED-ACTION PREPARATIONS; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; FEMALE; HUMANS; MALE; MIDDLE AGED; SEROTONIN UPTAKE INHIBITORS; SOCIAL ADJUSTMENT;

EID: 3342943547     PISSN: 09249338     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eurpsy.2004.05.010     Document Type: Article

References (34)

1. Allgulander C., Hackett D., Salinas E. Venlafaxine extended release (ER) in the treatment of generalised anxiety disorder: twenty-four-week placebo-controlled dose-ranging study. Br J Psychiatry. 179:2001;15-22
2. American Psychiatric Association. DSM-IV: diagnostic and statistical manual of mental disorders. 4th ed:1994;American Psychiatric Association, Washington (DC)
3. Anderson D.J., Noyes R. Jr, Crowe R.R. A comparison of panic disorder and generalized anxiety disorder. Am J Psychiatry. 141:1984;572-575
4. Andrews J.M., Ninan P.T., Nemeroff C.B. Venlafaxine: a novel antidepressant that has a dual mechanism of action. Depression. 4:1996;48-56
5. Barlow D.H., Blanchard E.B., Vermilyea J.A., Vermilyea B.B., DiNardo P.A. Generalized anxiety and generalized anxiety disorder: description and reconceptualisation. Am J Psychiatry. 143:1986;40-44
6. Davidson J.R., DuPont R.L., Hedges D., Haskins J.T. Efficacy, safety, and tolerability of venlafaxine extended release and buspirone in outpatients with generalized anxiety disorder. J Clin Psychiatry. 60:1999;528-535
7. Faravelli C., Guerrini Degl'Innocenti B., Giardinelli L. Epidemiology of anxiety disorders in Florence. Acta Psychiatr Scand. 79:1989;308-312
8. Gelenberg A.J., Lydiard R.B., Rudolph R.L., Aguiar L., Haskins J.T., Salinas E. Efficacy of venlafaxine extended-release capsules in nondepressed outpatients with generalized anxiety disorder: a 6-month randomized controlled trial. JAMA. 283:2000;3082-3088
9. Guy W. National Institute of Mental Health (US). Psychopharmacology Research Branch. Early Clinical Drug Evaluation Program. ECDEU assessment manual for psychopharmacology. 1976;U.S. Dept. of Health, Education, and Welfare, Public Service, Alcohol, Drug Abuse, and Mental Health Administration, National Institute of Mental Health, Psychopharmacology Research Branch, Division of Extramural Research Programs, Rockville, MD. Revised ed
10. Hamilton M. The assessment of anxiety states by rating. Br J Med Psychol. 32:1959;50-55
11. Keller M. Role of serotonin and noradrenaline in social dysfunction: a review of data on reboxetine and the Social Adaptation Self-evaluation Scale (SASS). Gen. Hospital Psychiatry. 23:2001;15-19
12. Kessler R.C., Frank R.G. The impact of psychiatric disorders on work loss days. Psychol Med. 27:1997;861-873
13. Kessler R.C., McGonagle K.A., Zhao S., Nelson C.B., Hughes M., Eshleman S., et al. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey. Arch Gen Psychiatry. 51:1994;8-19
14. Khan A., Upton G.V., Rudolph R.L., Entsuah R., Leventer S.M. The use of venlafaxine in the treatment of major depression and major depression associated with anxiety: a dose-response study. J Clin Psychopharmacol. 18:1998;19-25
15. Leaf P.J., Weissman M.M., Myers J.K., Tischler G.L., Holzer C.E. 3d. Social factors related to psychiatric disorder: the Yale Epidemiologic Catchment Area study. Soc Psychiatry. 19:1984;53-61
16. Luty S.E., Joyce P.R., Mulder R.T. Comparison between noradrenergic and serotonergic medications using the social adjustment scale: is drive enhancement necessary for recovery of social functioning? J Psychopharmacol. 15:2001;257-264
17. Noyes R. Jr, Clarkson C., Crowe R.R., Yates W.R., McChesney C.M. A family study of generalized anxiety disorder. Am J Psychiatry. 144:1987;1019-1024
18. Pollack M.H., Zaninelli R., Goddard A., McCafferty J.P., Bellew K.M., Burnham D.B., et al. Paroxetine in the treatment of generalized anxiety disorder: results of a placebo-controlled, flexible-dosage trial. J Clin Psychiatry. 62:2001;350-357
19. Rickels K. Antianxiety therapy: potential value of long-term treatment. J Clin Psychiatry. 48:1987;7-11
20. Rickels K., Downing R., Schweizer E., Hassman H. Antidepressants for the treatment of generalized anxiety disorder. A placebo-controlled comparison of imipramine, trazodone, and diazepam. Arch Gen Psychiatry. 50:1993;884-895
21. Rickels K., Pollack M.H., Sheehan D.V., Haskins J.T. Efficacy of extended-release venlafaxine in nondepressed outpatients with generalized anxiety disorder. Am J Psychiatry. 157:2000;968-974
22. Rickels K., Schweizer E. The clinical course and long-term management of generalized anxiety disorder. J Clin Psychopharmacol. 10:1990;101S-110S
23. Robins L.N., Regier D.A. Psychiatric disorders in America: the epidemiologic catchment area study. 1991;Free Press, New York, NY
24. Souetre E., Lozet H., Cimarosti I., Martin P., Chignon J.M., Ades J., et al. Cost of anxiety disorders: impact of comorbidity. J Psychosom Res. 38:1994;151-160
25. Tse W.S., Bond A.J. Difference in serotonergic and noradrenergic regulation of human social behaviours. Psychopharmacol. 159:2002;216-221
26. Üstün T.B., Sartorius N. Mental illness in general health care: an international study. 1995;Wiley, Chichester, NY
27. van Praag H.M., Asnis G.M., Kahn R.S., et al. Mono-amines and abnormal behaviour. A multi-aminergic perspective. Br J Psychiatry. 157:1990;723-734
28. Wacker H.R., Mullejans R., Klein K.H., Battegay R. Identification of cases of anxiety disorders and affective disorders in the community according to ICD-10 and DSM-III-R by using the Composite International Diagnostic Interview (CIDI). Int J Methods Psychiatr Res. 2:1992;91-100
29. Weissman M., Staff M.H.S. SAS-SR social adjustment scale self-report technical manual. 1999
30. Weissman M.M., Bothwell S. Assessment of social adjustment by patient self-report. Arch Gen Psychiatry. 33:1976;1111-1115
31. Weissman M.M., Prusoff B.A., Thompson W.D., Harding P.S., Myers J.K. Social adjustment by self-report in a community sample and in psychiatric outpatients. J Nerv Ment Dis. 166:1978;317-326
32. Wittchen H.U., Zhao S., Kessler R.C., Eaton W.W. DSM-III-R generalized anxiety disorder in the National Comorbidity Survey. Arch Gen Psychiatry. 51:1994;355-364
33. Yonkers K.A., Warshaw M.G., Massion A.O., Keller M.B. Phenomenology and course of generalised anxiety disorder. Br J Psychiatry. 168:1996;308-313
34. Zigmond A.S., Snaith R.P. The hospital anxiety and depression scale. Acta Psychiatr Scand. 67:1983;361-370